You are here

  • Home
  • Archive
  • Volume 7, Issue 4
  • Review: glycoprotein IIb/IIIa inhibitors reduced death or myocardial infarction in acute coronary syndromes not routinely scheduled for revascularisation

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: glycoprotein IIb/IIIa inhibitors reduced death or myocardial infarction in acute coronary syndromes not routinely scheduled for revascularisation

https://doi.org/10.1136/ebm.7.4.108

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Lancet 359, 189; Boersma E, Harrington RA, Moliterno DJ, et al.. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.. Jan 19;. :. –98.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with acute coronary syndromes not routinely scheduled for early coronary revascularisation, what is the efficacy and safety of glycoprotein (GP) IIb/IIIa inhibitors?

    Data sources

    Trials reported from 1990 were identified by searching Medline with the terms unstable angina, myocardial infarction, and platelet aggregation inhibition; reviewing scientific sessions abstracts in 3 cardiology journals; and scanning bibliographies of retrieved articles.

    Study selection

    Studies were selected if they randomly allocated ≥ 1000 patients who had acute coronary syndromes without persistent ST-segment elevation to a GP IIb/IIIa inhibitor or to placebo or control treatment and if early (< 48 h) coronary revascularisation during drug infusion was not recommended.

    Data extraction

    Data from individual patients were extracted on baseline characteristics (age, sex, cardiac history and medication, blood pressure, and heart rate), medication detail, dates and times of randomisation, …

    View Full Text

    Footnotes

    • Source of funding: not stated.

    • For correspondence: Dr E Boersma, University Hospital Rotterdam, Rotterdam, The Netherlands. boersma{at}thch.azr.nl.